Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series
Journal of Child and Adolescent Psychopharmacology · 2023
DOI: 10.1089/cap.2023.0049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2023. Verfasst von Esther Moon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy-Behavioral Health Services, Riverside University Health System, Riverside, California, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Major Depressive Disorder. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Objective
The efficacy and safety of long-acting injectable (LAI) antipsychotics in the pediatric population is not well established due to limited evidence. This case series aims to describe off-label use of aripiprazole lauroxil (AL) LAI in adolescent inpatients, including findings on safety and readmission trends.
Methods
This was a retrospective chart review of patients who were initiated on AL LAI while admitted at a county-based adolescent psychiatric unit between March 2021 and March 2023. Data comprised sociodemographic and clinical characteristics, such as psychiatric diagnoses, prior antipsychotic trials, and history of nonadherence. Other observations of interest included tolerability of AL LAI and time to readmission.
Results
This analysis identified 12 adolescents who received AL LAI within a 2-year period. The mean age was 16 ± 1 years, and seven (58%) patients were female. There were varying primary psychiatric diagnoses, with the most common being bipolar disorder (25%), schizophrenia (17%), major depressive disorder with psychotic features (17%), and unspecified mood disorder (17%). Eleven (92%) patients had previously trialed at least one antipsychotic, with seven (58%) having exposure to oral aripiprazole before admission. Nonadherence was the driving factor for LAI consideration in all but one patient. AL LAI was well tolerated short term; one patient reported experiencing injection site pain, and one patient discontinued the LAI after discharge due to anxiety. Time to readmission ranged from 15 to 658 days for seven patients who were hospitalized again; two of the readmissions occurred within 1 month.
Conclusion
This is the first case series to describe initiation of AL LAI at an inpatient adolescent psychiatric unit. Our study illustrates that AL LAI may hold potential as an acceptably tolerated treatment in adolescents with varying psychiatric diagnoses. Further studies are needed to evaluate long-term safety and effectiveness of AL LAI in youth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy-Behavioral Health Services, Riverside University Health System, Riverside, California, USA.
ORCID-Profile: Esther Moon
Zitieren
APA
Moon, E., Kim, E., & Williams, A. (2023). Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2023.0049
Vancouver
Moon E, Kim E, Williams A. Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series. Journal of Child and Adolescent Psychopharmacology. 2023. doi:10.1089/cap.2023.0049
BibTeX
@article{Moon2023,
author = {Moon, Esther and Kim, Erika and Williams, Andrew},
title = {Initiation of Aripiprazole Lauroxil Long-Acting Injectable in Adolescents During Hospitalization: A Case Series},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2023},
doi = {10.1089/cap.2023.0049}
}
EUVIMED